LONDON, Feb 29 (Reuters) - AstraZeneca said a closely watched experimental cancer drug failed in a clinical trial when used on its own to treat mesothelioma, a rare lung and abdominal cancer, but it remained confident the drug had a role to play in combination treatments.
Tremelimumab failed to meet the primary endpoint of improving overall survival in hard-to-treat mesothelioma patients, the drugmaker said on Monday.
Tremelimumab is also being tested in combination with another of AstraZeneca’s immune-boosting drugs called durvalumab in multiple tumour types, including non-small cell lung cancer.
Reporting by Ben Hirschler; Editing by Kate Kelland
Our Standards: The Thomson Reuters Trust Principles.